-
-
Transplant / TransfusionTransplant / Transfusion
Innovative solutions supporting safe transfusion and transplantBEXS 12 The BEXS 12 system enables automated extraction of DNA from 12 blood samples (250 μL each) or viral nucleic acids from various clinical samples, achieving high purity and yield. FluoQube FluoQube® is a versatile system that integrates amplification and fluorescence reading, supporting FluoGene® kits and other real-time PCR protocols. Categories Manufacturers -
Point of CarePoint of Care
Rapid diagnostics delivering accurate results at patient side -
Software SolutionsSoftware Solutions
Streamlined software enhancing efficiency, accuracy, and patient careBank Manager Bank Manager is a web-based blood transfusion management system for UK hospitals, offering safe, efficient, and compliant multi-site management with centralized oversight and seamless integration with existing healthcare systems. POCnet POCnet transmits clinical data from medical devices to EMRs for clinician review and treatment support. Categories Manufacturers -
PBSPBS
Reliable phosphate buffer ensuring stability in laboratory applicationsPhosphate-buffered saline - 2 x 5 Litre Jerry Can 2 x 5L CE-marked PBS solution (pH 7.0, 290 mOsmol/kg) for cell research; 2-year unopened shelf life. Phosphate-buffered saline - Concentrate (X20) 10x250ml 20X PBS concentrate (10 x 250ml), ISO 13485:2016 certified, 2-year shelf life. Phosphate-buffered saline - 10 Litre Bag in a box 10L PBS solution (pH 7.0, 290 mOsmol/kg) in a bag-in-box, CE marked, 2-year unopened shelf life. Categories Manufacturers -
CompanyCompany 8959979
VAT: 185179082
Transplant / TransfusionSoftware Solutions -
MV140 Oral UTI Vaccine Research – Royal Berkshire NHS Foundation Trust
A new oral spray vaccine shows promise against recurrent UTIs, keeping half of participants infection-free for 9 years!
2025-04-29 16:55:01
Royal Berkshire Hospital conducted a long-term study on the MV140 vaccine, an oral spray designed to prevent recurrent UTIs. Administered as two sublingual sprays daily for three months, the vaccine demonstrated:
Royal Berkshire NHS Trust
Approximately 50% of participants remained infection-free nine years post-treatment.
Reduced severity of UTIs in those who did experience infections.
Enhanced patient quality of life, with many managing mild symptoms through increased hydration alone.
Royal Berkshire NHS Trust
theguardian.com
This research highlights the vaccine's potential as a safe, long-term preventive measure against recurrent UTIs.
Royal Berkshire NHS Trust
Share:
© Copyright 2025 - Sussex Biologicals Ltd